Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines

Vaccine

Volumn 25, Issue 5, 2007, Pages 834-845

  Craigo, Jodi K ^a   Durkin, Shannon ^a   Sturgeon, Timothy J ^a   Tagmyer, Tara ^a   Cook, Sheila J ^b   Issel, Charles J ^b   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dexamethasone; EIAV; Immune suppression; Live attenuated; Vaccine

Indexed keywords

DEXAMETHASONE; EQUINE INFECTIOUS ANEMIA VIRUS VACCINE; LIVE VACCINE; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EQUINE INFECTIOUS ANEMIA VIRUS; GENE AMPLIFICATION; HORSE; IMMUNOSUPPRESSIVE TREATMENT; INSTRUMENT STERILIZATION; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RETROVIRUS INFECTION; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; DEXAMETHASONE; EQUINE INFECTIOUS ANEMIA; FEMALE; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; MALE; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 33845286550     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.040     Document Type: Article

References (44)

1. Li F., Craigo J.K., Howe L., Steckbeck J.D., Cook S., Issel C., et al. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77 13 (2003) 7244-7253
2. Craigo J.K., Li F., Steckbeck J.D., Durkin S., Howe L., Cook S.J., et al. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 79 5 (2005) 2666-2677
3. Mims C.A. The pathogenesis of infectious diseases. 3rd ed. (1987), Academic, San Diego
4. Melink J.A. Vaccines. 2nd ed. (1994), Academic, San Diego
5. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5 (1999) 194-203
6. Das A.T., Baldwin C.E., Vink M., and Berkhout B. Improving the safety of a conditional-live human immunodeficiency virus Type 1 vaccine by controlling both gene expression and cell entry. J Virol 79 6 (2005) 3855-3858
7. Berkhout B., Verhoef K., van Wamel J.L.a.B., and Back N.K.a.T. Genetic instability of live-attenuated human immunodeficiency virus type 1 vaccine strains. J Virol 73 2 (1999) 1138-1145
8. Desrosiers R.C. Prospects for live attenuated HIV. Nat Med 4 (1998) 982
9. Almond N., and Stott J. Live attenuated SIV-a model of a vaccine for AIDS. Immunol Lett 66 1-3 (1999) 167-170
10. Johnson R.P. Live attenuated AIDS vaccines: hazards and hopes. Nat Med 5 (1999) 154-155
11. Blower S.M., Koelle K., Kirschner D.E., and Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. PNAS 98 6 (2001) 3618
12. Goulder P.J.R., and Walker B.D. HIV-1 superinfection-a word of caution. N Engl J Med 347 (2002) 756-758
13. Learmont J.C., Geczy A.F., Mills J., Ashton L.J., Raynes-Greenow C.H., Garsia R.J., et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1-a report from the Sydney Blood Bank Cohort. N Engl J Med 340 22 (1999) 1715
14. Zhang B., Jin S., Jin J., Li F., and Montelaro R.C. A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus. Proc Natl Acad Sci USA 102 28 (2005) 9918-9923
15. Hammond S.A., Li F., McKeon Sr. B.M., Cook S.J., Issel C.J., and Montelaro R.C. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 74 13 (2000) 5968-5981
16. Harrold S.M., Cook S.J., Cook R.F., Rushlow K.E., Issel C.J., and Montelaro R.C. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74 7 (2000) 3112-3121
17. Montelaro R.C., Ball J.M., and Rushlow K. Equine Retroviruses. In: Levy J.A. (Ed). The Retroviridae (1993), Plenum Press, New York, NY 257-360
18. Kono Y., hirasawa K., Fukunaga Y., and Taniguchi T. Recrudesence of equine infectious anemia by treatment with immunosuppressive drugs. Nat Inst Anim Hlth Q 16 (1976) 8-15
19. Hammond S.A., Cook S.J., Falo Jr. L.D., Issel C.J., and Montelaro R.C. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 254 (1999) 37-49
20. Raabe M.L., Issel C.J., Cook S.J., Cook R.F., Woodson B., and Montelaro R.C. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 245 (1998) 151-162
21. Wang S.Z., Rushlow K.E., Issel C.J., Cook R.F., Cook S.J., Raabe M.L., et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199 (1994) 247-251
22. Issel C.J., Horohov D.W., Lea D.F., Adams Jr. W.V., Hagius S.D., McManus J.M., et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 66 (1992) 3398-3408
23. Montelaro R.C., Grund C.H., Raabe M.R., Woodson B., Cook R.F., Cook S.J., et al. Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. AIDS Res Hum Retroviruses 12 (1996) 413-415
24. Raabe M.L., Issel C.J., and Montelaro R.C. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology 259 (1999) 416-427
25. Hammond S.A., Raabe M.L., Issel C.J., and Montelaro R.C. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 262 (1999) 416-430
26. Li F., Puffer B.A., and Montelaro R.C. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 72 (1998) 8344-8348
27. Cook R.F., Leroux C., Cook S.J., Berger S.L., Lichtenstein D.L., Ghabrial N.N., et al. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J Virol 72 (1998) 1383-1393
28. Leroux C., Issel C., and Montelaro R.C. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 71 12 (1997) 9627-9639
29. Grund C.H., Lechman E.R., Issel C.J., Montelaro R.C., and Rushlow K.E. Lentivirus cross-reactive determinants present in the capsid protein of equine infectious anaemia virus. J Gen Virol 75 Pt 3 (1994) 657-662
30. Raabe M.R., Issel C.J., and Montelaro R.C. Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus. J Virol Methods 71 (1998) 87-104
31. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., and Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71 5 (1997) 3840-3852
32. Tumas D.B., Hines M.T., Perryman L.E., Davis W.C., and McGuire T.C. Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anemia virus-carrier horses. J Gen Virol 75 (1994) 959-968
33. Craigo J.K., Leroux C., Howe L., Steckbeck J.D., Cook S.J., Issel C.J., et al. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J Gen Virol 83 6 (2002) 1353-1359
34. Baus E., Andris F., Dubois P.M., Urbain J., and Leo O. Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes. J Immunol 156 12 (1996) 4555-4561
35. Hodgin E.C., McGuire T.C., Perryman L.E., and Grant B.D. Evaluation of delayed hypersensitivity responses in normal horses and immunodeficient foals. Am J Vet Res 39 7 (1978) 1161-1167
36. Coggins L., and Norcross N.L. Immunodiffusion reaction in equine infectious anemia. Cornell Vet 60 (1970) 330-335
37. Cook R.F., Cook S.J., Li F.L., Montelaro R.C., and Issel C.J. Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV). J Virol Methods 105 1 (2002) 171-179
38. Montelaro R.C., Cole K.S., and Hammond S.A. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 14 Suppl. 3 (1998) S255-S259
39. Cole K.S., Rowles J.L., Jagerski B.A., Murphey-Corb M., Unangst T., Clements J.E., et al. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 71 7 (1997) 5069-5079
40. Cole K.S., Murphey-Corb M., Narayan O., Joag S.V., Shaw G.M., and Montelaro R.C. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol 72 10 (1998) 7852-7859
41. Huber V.C., and McCullers J.A. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis 193 5 (2006) 677-684
42. Mackay G.A., Liu Z., Singh D.K., Smith M.S., Mukherjee S., Sheffer D., et al. Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus. J Immunol 173 6 (2004) 4100-4107
43. Cole K.S., Rowles J.L., Murphey-Corb M., Clements J.E., Robinson J., and Montelaro R.C. A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys. J Med Primatol 26 (1997) 51-58
44. Shen R-XaWZ. Development and use of an equine infectious anemia donkey leucocyte attenuated vaccine. EIAV: a national review of policies, programs, and future objectives; 1985.